{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:44:14Z","timestamp":1773798254451,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10157-018-1584-0","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T10:36:11Z","timestamp":1525948571000},"page":"1309-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method"],"prefix":"10.1007","volume":"22","clinical-trial-number":[{"clinical-trial-number":"umin000030503","registry":"10.18810\/umin-japan"}],"author":[{"given":"Eri","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-5933","authenticated-orcid":false,"given":"Daijo","family":"Inaguma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.ajkd.2010.12.027","volume":"58","author":"GB John","year":"2011","unstructured":"John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis. 2011;58:127\u201334.","journal-title":"Am J Kidney Dis"},{"key":"1584_CR2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2215\/CJN.02640310","volume":"5","author":"OM Gutierrez","year":"2010","unstructured":"Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis. Clin J Am Soc Nephrol. 2010;5:1710\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1584_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429\u201335.","journal-title":"J Bone Miner Res"},{"key":"1584_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Group KDIGOKC-MUW","year":"2017","unstructured":"Group KDIGOKC-MUW. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1\u201359.","journal-title":"Kidney Int Suppl"},{"key":"1584_CR5","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393\u2013408.","journal-title":"J Clin Invest"},{"key":"1584_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545\u201352.","journal-title":"Circulation"},{"key":"1584_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","volume":"90","author":"S Singh","year":"2016","unstructured":"Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985\u201396.","journal-title":"Kidney Int"},{"key":"1584_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","volume":"91","author":"J Munoz Mendoza","year":"2017","unstructured":"Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2017;91:711\u20139.","journal-title":"Kidney Int"},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.21873\/invivo.11038","volume":"31","author":"E Georgiadou","year":"2017","unstructured":"Georgiadou E, Marketou H, Trovas G, Dontas I, Papaioannou N, Makris K, Galanos A, Papavassiliou AG. Effect of calcitriol on FGF23 level in healthy adults and its dependence on phosphate level. In Vivo. 2017;31:145\u201350.","journal-title":"In Vivo"},{"key":"1584_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2012-2790","volume":"98","author":"C Turner","year":"2013","unstructured":"Turner C, Dalton N, Inaoui R, Fogelman I, Fraser WD, Hampson G. Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency. J Clin Endocrinol Metab. 2013;98:550\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"1584_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","volume":"103","author":"TK Barthel","year":"2007","unstructured":"Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HAT, Hsieh JC, Slater SA, Hsieh G, Kaczmarska M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR. 1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007;103:381\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","volume":"27","author":"D Hansen","year":"2012","unstructured":"Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant. 2012;27:2263\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1584_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.numecd.2016.03.008","volume":"26","author":"C Zoccali","year":"2016","unstructured":"Zoccali C, Torino C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Ghiadoni L, Thadhani R, Tripepi G, Mallamaci F. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients. Nutr Metab Cardiovasc Dis. 2016;26:581\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1584_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"1584_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1584_CR16","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","volume":"26","author":"E Gonzalez-Parra","year":"2011","unstructured":"Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011;26:2567\u201371.","journal-title":"Nephrol Dial Transplant"},{"key":"1584_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"YC Li","year":"2002","unstructured":"Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229\u201338.","journal-title":"J Clin Invest"},{"key":"1584_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ki.2008.101","volume":"74","author":"C Zhou","year":"2008","unstructured":"Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74:170\u20139.","journal-title":"Kidney Int"},{"key":"1584_CR19","doi-asserted-by":"publisher","first-page":"16810","DOI":"10.1073\/pnas.0611202104","volume":"104","author":"N Bodyak","year":"2007","unstructured":"Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007;104:16810\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1584_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52:249\u201355.","journal-title":"Hypertension"},{"key":"1584_CR21","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D de Zeeuw","year":"2010","unstructured":"de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543\u201351.","journal-title":"Lancet"},{"key":"1584_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5114\/aoms.2012.27271","volume":"8","author":"M Caprio","year":"2012","unstructured":"Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial function and dysfunction. Arch Med Sci. 2012;8:4\u20135.","journal-title":"Arch Med Sci"},{"key":"1584_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10157-009-0233-z","volume":"14","author":"S Sugiura","year":"2010","unstructured":"Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K, Yuzawa Y, Matsuo S. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol. 2010;14:43\u201350.","journal-title":"Clin Exp Nephrol"},{"key":"1584_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","volume":"168","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168:397\u2013403.","journal-title":"Arch Intern Med"},{"key":"1584_CR25","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1681\/ASN.2007111164","volume":"19","author":"AB Shoben","year":"2008","unstructured":"Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19:1613\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1584_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ndt\/gfg513","volume":"19","author":"T Shoji","year":"2004","unstructured":"Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"1584_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000479894","volume":"8","author":"D Inaguma","year":"2017","unstructured":"Inaguma D, Ito E, Koide S, Takahashi K, Hayashi H, Hasegawa M, Yuzawa Y. combination therapy with renin-angiotensin system blockers and vitamin D receptor activators for predialysis patients is associated with the incidence of cardiovascular events after dialysis initiation: a multicenter nonrandomized prospective cohort study. Cardiorenal Med. 2017;8:71\u201381.","journal-title":"Cardiorenal Med"},{"key":"1584_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000346846","volume":"37","author":"F Duranton","year":"2013","unstructured":"Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37:239\u201348.","journal-title":"Am J Nephrol"},{"key":"1584_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307:674\u201384.","journal-title":"JAMA"},{"key":"1584_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AY Wang","year":"2014","unstructured":"Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial. J Am Soc Nephrol. 2014;25:175\u201386.","journal-title":"J Am Soc Nephrol"},{"key":"1584_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mce.2016.05.008","volume":"432","author":"RG Erben","year":"2016","unstructured":"Erben RG. Update on FGF23 and Klotho signaling. Mol Cell Endocrinol. 2016;432:56\u201365.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-018-1584-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1584-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1584-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:22:46Z","timestamp":1628590966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-018-1584-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1584-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study will be conducted according to the Ethical Guidelines for Clinical Research of the Japanese Ministry of Health, Labour, and Welfare (created July 30, 2003; full revision December 28, 2004; full revision July 31, 2008) and the Helsinki Declaration (revised 2013), and has been approved by the clinical research ethics committees (Approval Number: HM17-194). The subjects will receive oral and written explanations of the purpose of the study and will provide consent. Trial registration is UMIN000030503. Registered January 20, 2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and concent to participate"}},{"value":"YY has received research support grants from Otsuka Pharmaceutical Co., Ltd, Kyowa Hakko Kirin Co., Ltd, and Chugai Pharmaceutical Co., Ltd. DI has received lecture fees from Kyowa Hakko Kirin Co., Ltd. and Ono Pharmaceutical Co., Ltd. Other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}